Clevidipine: A novel ultra-short-acting calcium antagonist

Lendita Prlesi, Angela Cheng-Lai

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hypertension is the most common cardiovascular condition in the United States. It can lead to end organ damage and increased mortality risk if it is not properly controlled. In most situations where blood pressure has to be brought down quickly, an intravenous agent with a quick onset of action is often used. Clevidipine is the first third-generation IV dihydropyridine calcium channel blocker that has a high degree of vascular selectivity and an ultra-fast onset and offset of blood pressure lowering effect. In various clinical trials, clevidipine has shown to be safe and effective in controlling acute blood pressure elevations in patients with hypertensive emergencies, preoperative hypertension, and postoperative hypertension. The most common adverse events noted are atrial fibrillation, nausea, headache, and acute renal failure. Overall, clevidipine is a useful addition to available intravenous agents in reducing blood pressure during acute situations. The acceptance of this agent to hospital formularies may ultimately depend on its perceived ease of administration, clinically relevant benefits over other available agents, and acquisition costs.

Original languageEnglish (US)
Pages (from-to)147-152
Number of pages6
JournalCardiology in Review
Volume17
Issue number3
DOIs
StatePublished - May 2009

Fingerprint

Blood Pressure
Calcium
Hypertension
Hospital Formularies
Reducing Agents
Calcium Channel Blockers
Acute Kidney Injury
Atrial Fibrillation
Nausea
Blood Vessels
Headache
Emergencies
Clinical Trials
Costs and Cost Analysis
Mortality
clevidipine
1,4-dihydropyridine

Keywords

  • Calcium antagonists
  • Clevidipine
  • Perioperative hypertension
  • Severe hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clevidipine : A novel ultra-short-acting calcium antagonist. / Prlesi, Lendita; Cheng-Lai, Angela.

In: Cardiology in Review, Vol. 17, No. 3, 05.2009, p. 147-152.

Research output: Contribution to journalArticle

@article{0714c162eddc45d0bbdbd97dec4ad5f6,
title = "Clevidipine: A novel ultra-short-acting calcium antagonist",
abstract = "Hypertension is the most common cardiovascular condition in the United States. It can lead to end organ damage and increased mortality risk if it is not properly controlled. In most situations where blood pressure has to be brought down quickly, an intravenous agent with a quick onset of action is often used. Clevidipine is the first third-generation IV dihydropyridine calcium channel blocker that has a high degree of vascular selectivity and an ultra-fast onset and offset of blood pressure lowering effect. In various clinical trials, clevidipine has shown to be safe and effective in controlling acute blood pressure elevations in patients with hypertensive emergencies, preoperative hypertension, and postoperative hypertension. The most common adverse events noted are atrial fibrillation, nausea, headache, and acute renal failure. Overall, clevidipine is a useful addition to available intravenous agents in reducing blood pressure during acute situations. The acceptance of this agent to hospital formularies may ultimately depend on its perceived ease of administration, clinically relevant benefits over other available agents, and acquisition costs.",
keywords = "Calcium antagonists, Clevidipine, Perioperative hypertension, Severe hypertension",
author = "Lendita Prlesi and Angela Cheng-Lai",
year = "2009",
month = "5",
doi = "10.1097/CRD.0b013e31819fe23c",
language = "English (US)",
volume = "17",
pages = "147--152",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Clevidipine

T2 - A novel ultra-short-acting calcium antagonist

AU - Prlesi, Lendita

AU - Cheng-Lai, Angela

PY - 2009/5

Y1 - 2009/5

N2 - Hypertension is the most common cardiovascular condition in the United States. It can lead to end organ damage and increased mortality risk if it is not properly controlled. In most situations where blood pressure has to be brought down quickly, an intravenous agent with a quick onset of action is often used. Clevidipine is the first third-generation IV dihydropyridine calcium channel blocker that has a high degree of vascular selectivity and an ultra-fast onset and offset of blood pressure lowering effect. In various clinical trials, clevidipine has shown to be safe and effective in controlling acute blood pressure elevations in patients with hypertensive emergencies, preoperative hypertension, and postoperative hypertension. The most common adverse events noted are atrial fibrillation, nausea, headache, and acute renal failure. Overall, clevidipine is a useful addition to available intravenous agents in reducing blood pressure during acute situations. The acceptance of this agent to hospital formularies may ultimately depend on its perceived ease of administration, clinically relevant benefits over other available agents, and acquisition costs.

AB - Hypertension is the most common cardiovascular condition in the United States. It can lead to end organ damage and increased mortality risk if it is not properly controlled. In most situations where blood pressure has to be brought down quickly, an intravenous agent with a quick onset of action is often used. Clevidipine is the first third-generation IV dihydropyridine calcium channel blocker that has a high degree of vascular selectivity and an ultra-fast onset and offset of blood pressure lowering effect. In various clinical trials, clevidipine has shown to be safe and effective in controlling acute blood pressure elevations in patients with hypertensive emergencies, preoperative hypertension, and postoperative hypertension. The most common adverse events noted are atrial fibrillation, nausea, headache, and acute renal failure. Overall, clevidipine is a useful addition to available intravenous agents in reducing blood pressure during acute situations. The acceptance of this agent to hospital formularies may ultimately depend on its perceived ease of administration, clinically relevant benefits over other available agents, and acquisition costs.

KW - Calcium antagonists

KW - Clevidipine

KW - Perioperative hypertension

KW - Severe hypertension

UR - http://www.scopus.com/inward/record.url?scp=67549093680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67549093680&partnerID=8YFLogxK

U2 - 10.1097/CRD.0b013e31819fe23c

DO - 10.1097/CRD.0b013e31819fe23c

M3 - Article

C2 - 19384089

AN - SCOPUS:67549093680

VL - 17

SP - 147

EP - 152

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 3

ER -